Breast cancer chemotherapy: perioperative considerations in breast reconstruction.
D000328:Adult; D000477:Alkylating Agents / Q000009:adverse effects; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001940:Breast / Q000601:surgery*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008408:Mastectomy; D008558:Melphalan / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D013518:Surgery, Plastic; D013629:Tamoxifen / Q000009:adverse effects; D013852:Thiotepa / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects
D000477:Alkylating Agents; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D013629:Tamoxifen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D008558:Melphalan; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate